丹参素对大鼠肥厚离体心脏缺血再灌注损伤诱发的心律失常的影响(英文)

Effects of Danshensu on the Incidence of Ischemia-reperfusion Induced Arrhythmia in Hypertrophy Rat Heart

目的:研究丹参素对大鼠心脏肥厚及其缺血再灌注损伤诱发心律失常的影响,并探讨其与NO的关系。方法:用L-甲状腺素连续按2mg·kg-1连续给予10d,每天一次,制备心肌肥厚模型。治疗组从第4天开始至第10天,给予丹参素或缬沙坦进行治疗,用Langerdorff装置进行大鼠心脏离体缺血再灌注实验,结扎冠状动脉并复灌,观察VT、VF发生率,起始时间及持续时间;测定血清NO含量及NOS活性。结果:与正常组相比,肥厚组心脏缺血再灌注心律失常发生率,VT、VF发生时间、持续时间明显增加,NO含量及eNOS活性明显下降(P<0.05);丹参素及缬沙坦预治疗能有效的抑制缺血再灌注损伤诱发的心律失常的发生率;丹参素及缬沙坦能抑制大鼠心肌肥厚,明显升高NO含量及eNOS活性至正常水平。结论:丹参素对于L-甲状腺素诱发的大鼠心肌肥厚及其离体心脏缺血再灌注诱发的心律失常具有一定的保护作用,这种保护作用主要与保护eNOS活性,增加NO含量有关。

AIM： To study the effects of Danshensu on the incidence of ischemia reperfusion （I/R） induced arrhythmia in hypertrophy rat and to explore its relationship with NO. METHODS： L-thyroxine （2 mg·kg^-1·d^-1） po 10 d was used to establish myocardial hypertrophy model; rats were administered with either Danshensu or Valsartan from the 4th day to the 10th day. Ischemia and reperfusion arrhythmia was produced by ligating 20 min and loosing the coronary artery in Langendorff isolated rat heart; ECG was recorded on VT and VF incidence rate, onset time and duration time. Blood serums NO contents and NOS activity were determined and heart weight index was measured. RESULTS： Compared with the control group, VF incidence of I/R episode was increased in the hypertrophy group; serum NO content was significantly reduced and eNOS activity was significantly dropped in the hypertrophy group （P〈0.05）. Danshensu and Valsartan pretreatment groups can effectively inhibit I/R arrhythmia, ventricular arrhythmia incidence rate, onset time and duration time of VT and VT were lower than in hypertrophy groups; Danshensu and Valsartan were effective in preventing hypertrophy progression in rats; serum NO content and eNOS activity were significantly enhanced toward normal range. CONCLUSION： Danshensu has shown a significant cardioprotection against I/R injury in hypertrophy rat heart and the cardioprotection of Danshensu is partly mediated by protecting of eNOS activity and increasing NO content, the effects are similar to those of Valsartan.